Several cases have recently been reported suggesting that treatment with CytoDyn’s leronlimab restores immune function and achieves clinical improvement in people with critical COVID-19 (https://www.sciencedirect.com/science/article/pii/S2589909021000034) (https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1583/5932277). A new article, published online on March 23, 2021 in the Journal of Translational Autoimmuity, reports on an additional case of a critically ill COVID-19 person who was successfully treated with leronlimab. This person had been on extracorporeal membrane oxygenation (ECMO) for an extended period of time (66 days) before receiving four doses of leronlimab. The male subject received his first dose of leronlimab on Day 79 of hospitalization. He was weaned off ECMO by Day 84 and discharged from the ECMO intensive care unit on Day 91. He continues to improve and is currently in rehabilitation. The case was reported by corresponding author, Soheir Elneil, MD, PhD, University College London, National Hospital for Neurology and Neurosurgery, London, UK; Jacob Lalezari, MD, CEO & Director, Quest Diagnostis Services, San Francisco, California; and Nader Pourhassan, PhD, CEO & President & Director, CytoDyn, Seattle, Washington. In their abstract, the authors noted that the number of confirmed cases of infection with SARS-CoV-2, the virus causing coronavirus disease 2019 (COVID-19), continues to increase and is associated with substantial morbidity and mortality in virtually every country in the world. The authors noted that, “although in the long-term mass vaccinations remains the most promising approach to control the pandemic, evidence suggests that new variants of the virus have emerged that may be able to evade the immune responses triggered by current vaccines.
Login Or Register To Read Full Story